000			02308 a2200577 4500
005			20250517132231.0
264		0	_c20170808
008			201708s 0 0 eng d
022			_a1527-7755
024	7		_a10.1200/JCO.2016.69.9538 _2doi
040			_aNLM _beng _cNLM
100	1		_aMoore, Kathleen N
245	0	0	_aSafety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. _h[electronic resource]
260			_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cApr 2017
300			_a1112-1118 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Journal Article
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntibodies, Monoclonal, Humanized _xadverse effects
650	0	4	_aAntineoplastic Agents _xadverse effects
650	0	4	_aDiarrhea _xchemically induced
650	0	4	_aDisease-Free Survival
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aFallopian Tube Neoplasms _xchemistry
650	0	4	_aFatigue _xchemically induced
650	0	4	_aFemale
650	0	4	_aFolate Receptor 1 _xanalysis
650	0	4	_aHumans
650	0	4	_aHypotension _xchemically induced
650	0	4	_aImmunoconjugates _xadverse effects
650	0	4	_aMaytansine _xadverse effects
650	0	4	_aMiddle Aged
650	0	4	_aNausea _xchemically induced
650	0	4	_aOvarian Neoplasms _xchemistry
650	0	4	_aPeritoneal Neoplasms _xchemistry
650	0	4	_aPlatinum Compounds _xtherapeutic use
650	0	4	_aResponse Evaluation Criteria in Solid Tumors
650	0	4	_aRetreatment
650	0	4	_aVision Disorders _xchemically induced
700	1		_aMartin, Lainie P
700	1		_aO'Malley, David M
700	1		_aMatulonis, Ursula A
700	1		_aKonner, Jason A
700	1		_aPerez, Raymond P
700	1		_aBauer, Todd M
700	1		_aRuiz-Soto, Rodrigo
700	1		_aBirrer, Michael J
773	0		_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 35 _gno. 10 _gp. 1112-1118
856	4	0	_uhttps://doi.org/10.1200/JCO.2016.69.9538 _zAvailable from publisher's website
999			_c26736815 _d26736815